Loading clinical trials...
Loading clinical trials...
A Phase II Study of PHA-739358 in Patients With Metastatic Hormone Refractory Prostate Cancer
To assess the antitumor activity of PHA-739358 administered as IV infusion according to two different dose schedules in metastatic HRPC patients progressing on standard, docetaxel-based 1st-line chemotherapy for HRPC based on PSA response, and to select the best dose schedule for further investigation.
Age
18 - No limit years
Sex
MALE
Healthy Volunteers
No
Nerviano Medical Sciences. Clinical Research Dept.
Nerviano, Milano, Italy
Start Date
September 1, 2007
Primary Completion Date
March 1, 2011
Completion Date
April 1, 2011
Last Updated
May 28, 2014
118
ACTUAL participants
PHA-739358
DRUG
PHA-739358
DRUG
Lead Sponsor
Nerviano Medical Sciences
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions